Pr ecis: Binding of a prostate cancer cell receptor to a proteinase expressed by myeloid cells in the bone microenvironment drives the most common type of metastasis during prostate cancer progression, with immediate implications for molecular prognosis and intervention. Pr ecis: A TWIST1-induced histone methylation event at the HOXA9 promoter reactivates its expression during prostate cancer metastasis, offering a candidate therapeutic target.
Pr ecis: Dynamic logic models of signaling pathways based on perturbation data provide biomarkers of efficacy for drugs for which no genomic marker exist and suggest strategies to overcome drug resistance. 
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